A detailed history of Northern Trust Corp transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 131,445 shares of MDGL stock, worth $28.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
131,445
Previous 131,358 0.07%
Holding current value
$28.6 Million
Previous $35.1 Million 4.98%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$193.33 - $291.99 $16,819 - $25,403
87 Added 0.07%
131,445 $36.8 Million
Q1 2024

May 14, 2024

SELL
$171.37 - $283.23 $573,746 - $948,254
-3,348 Reduced 2.49%
131,358 $35.1 Million
Q4 2023

Feb 13, 2024

BUY
$120.4 - $237.13 $1.33 Million - $2.62 Million
11,057 Added 8.94%
134,706 $31.2 Million
Q3 2023

Nov 13, 2023

BUY
$146.04 - $225.78 $153,342 - $237,069
1,050 Added 0.86%
123,649 $18.1 Million
Q2 2023

Aug 11, 2023

BUY
$203.88 - $312.0 $1.86 Million - $2.84 Million
9,114 Added 8.03%
122,599 $28.3 Million
Q1 2023

May 15, 2023

BUY
$231.06 - $307.08 $460,271 - $611,703
1,992 Added 1.79%
113,485 $27.5 Million
Q4 2022

Feb 13, 2023

SELL
$58.39 - $296.54 $111,641 - $566,984
-1,912 Reduced 1.69%
111,493 $32.4 Million
Q3 2022

Nov 14, 2022

SELL
$60.57 - $79.51 $96,306 - $126,420
-1,590 Reduced 1.38%
113,405 $7.37 Million
Q2 2022

Aug 12, 2022

BUY
$58.04 - $100.2 $208,537 - $360,018
3,593 Added 3.23%
114,995 $8.23 Million
Q1 2022

May 13, 2022

SELL
$55.89 - $101.89 $308,959 - $563,247
-5,528 Reduced 4.73%
111,402 $10.9 Million
Q4 2021

Feb 08, 2022

BUY
$72.34 - $95.09 $353,236 - $464,324
4,883 Added 4.36%
116,930 $9.91 Million
Q3 2021

Nov 15, 2021

SELL
$78.35 - $105.02 $220,555 - $295,631
-2,815 Reduced 2.45%
112,047 $8.94 Million
Q2 2021

Aug 13, 2021

BUY
$97.2 - $137.59 $1.39 Million - $1.97 Million
14,284 Added 14.2%
114,862 $11.2 Million
Q1 2021

May 12, 2021

SELL
$108.54 - $125.2 $373,920 - $431,314
-3,445 Reduced 3.31%
100,578 $11.8 Million
Q4 2020

Feb 11, 2021

SELL
$110.06 - $133.7 $204,381 - $248,280
-1,857 Reduced 1.75%
104,023 $11.6 Million
Q3 2020

Nov 16, 2020

SELL
$99.78 - $124.21 $721,209 - $897,789
-7,228 Reduced 6.39%
105,880 $12.6 Million
Q2 2020

Aug 14, 2020

BUY
$60.13 - $125.71 $116,171 - $242,871
1,932 Added 1.74%
113,108 $12.8 Million
Q1 2020

May 14, 2020

BUY
$66.76 - $93.49 $1.03 Million - $1.44 Million
15,451 Added 16.14%
111,176 $7.42 Million
Q4 2019

Feb 14, 2020

SELL
$84.28 - $118.5 $755,317 - $1.06 Million
-8,962 Reduced 8.56%
95,725 $8.72 Million
Q3 2019

Nov 13, 2019

BUY
$84.4 - $106.53 $530,032 - $669,008
6,280 Added 6.38%
104,687 $9.03 Million
Q2 2019

Aug 13, 2019

BUY
$91.13 - $142.5 $194,653 - $304,380
2,136 Added 2.22%
98,407 $10.3 Million
Q1 2019

May 13, 2019

BUY
$103.48 - $143.84 $129,039 - $179,368
1,247 Added 1.31%
96,271 $12.1 Million
Q4 2018

Feb 12, 2019

SELL
$94.77 - $215.54 $739,585 - $1.68 Million
-7,804 Reduced 7.59%
95,024 $10.7 Million
Q3 2018

Nov 14, 2018

BUY
$207.3 - $300.31 $2.52 Million - $3.65 Million
12,165 Added 13.42%
102,828 $22 Million
Q2 2018

Sep 18, 2018

SELL
$101.55 - $313.9 $83,271 - $257,397
-820 Reduced 0.9%
90,663 $25.4 Million
Q2 2018

Aug 14, 2018

BUY
$101.55 - $313.9 $1.81 Million - $5.6 Million
17,843 Added 24.23%
91,483 $25.6 Million
Q1 2018

May 09, 2018

BUY
$93.35 - $149.04 $783,486 - $1.25 Million
8,393 Added 12.86%
73,640 $8.6 Million
Q4 2017

Feb 14, 2018

BUY
$39.35 - $97.37 $489,946 - $1.21 Million
12,451 Added 23.58%
65,247 $5.99 Million
Q3 2017

Nov 13, 2017

BUY
$15.48 - $46.19 $817,282 - $2.44 Million
52,796
52,796 $2.37 Million

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $3.72B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.